Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
Portfolio Pulse from
Elicio Therapeutics presented updated results from its ELI-002 Phase 1 AMPLIFY-201 study at the ESMO Immuno-Oncology Congress 2024. The study showed a 16.3-month median recurrence-free survival and a 28.9-month median overall survival in the full study population.
December 12, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Elicio Therapeutics presented promising updated results for its ELI-002 Phase 1 study, indicating potential positive impacts on its stock price due to improved survival rates.
The updated Phase 1 results for ELI-002 show improved survival rates, which is a positive indicator for the efficacy of the treatment. This could lead to increased investor confidence and a potential rise in stock price for Elicio Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90